Compare EOT & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOT | BDSX |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Precision Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 264.2M | 276.2M |
| IPO Year | 2009 | 2020 |
| Metric | EOT | BDSX |
|---|---|---|
| Price | $15.92 | $29.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 36.4K | ★ 88.8K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | N/A | $19.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $15.75 | $5.26 |
| 52 Week High | $18.00 | $31.31 |
| Indicator | EOT | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 23.05 | 63.30 |
| Support Level | N/A | $19.26 |
| Resistance Level | $17.85 | $31.31 |
| Average True Range (ATR) | 0.27 | 1.59 |
| MACD | -0.09 | 0.10 |
| Stochastic Oscillator | 12.35 | 92.71 |
Eaton Vance National Municipal Opportunities Trust is a diversified, closed-end management investment company. The company's investment objective is to provide current income exempt from regular federal income tax and to achieve capital appreciation. The company invests a majority of its assets in debt obligations issued by or on behalf of states, territories, and possessions of the United States, including the District of Columbia, and their political subdivisions, agencies, or instrumentalities, the interest on which is exempt from regular federal income tax.
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.